CA2553237C - Production method - Google Patents

Production method Download PDF

Info

Publication number
CA2553237C
CA2553237C CA2553237A CA2553237A CA2553237C CA 2553237 C CA2553237 C CA 2553237C CA 2553237 A CA2553237 A CA 2553237A CA 2553237 A CA2553237 A CA 2553237A CA 2553237 C CA2553237 C CA 2553237C
Authority
CA
Canada
Prior art keywords
oxo
phenyl
reaction
oxazolidin
morpholinyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2553237A
Other languages
French (fr)
Other versions
CA2553237A1 (en
Inventor
Mathias Berwe
Christian Thomas
Joachim Rehse
Dirk Grotjohann
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer Intellectual Property GmbH
Original Assignee
Bayer Schering Pharma AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34716548&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CA2553237(C) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bayer Schering Pharma AG filed Critical Bayer Schering Pharma AG
Publication of CA2553237A1 publication Critical patent/CA2553237A1/en
Application granted granted Critical
Publication of CA2553237C publication Critical patent/CA2553237C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

The present invention- relates to a process for preparing 5-chloro-N-{{(5S) 2-oxo-3-[4-(3-oxo-4-morpholinyl)phenyl]-1,3-oxazolidin-5 yl}methyl)-2-thiophenecarboxamide starting from 2-[(2S)-2-oxiranylmethyl]-1H-isoindole-1,3(2H)-dione, 4-(4-aminophenyl)-3-morpholinone and 5-chlorothiophene-2-carbonyl chloride.

Description

PRODUCTION METHOD

The present invention relates to a process for preparing 5-chloro N-({(5S)-2-oxo-3-[4{3-oxo-4-morpholinyl)phenyl]-1,3-oxazolidin-5 yl}methyl)-2-thiophenecarboxamide starting from 2-[(2S)-
2-oxiranylmethyl]-1H-isoindole-1,3(2H)-dione, 4-(4-aminophenyl)-3-morpholinone and 5-chlorothiophene-2-carbonyl chloride. -The compound 5-chloro-N-({(5S)-2-oxo-3-[4-(3-oxo-4-morpholinyl)phenyl]-1,3-oxazolidin-5 yl}-methyl)-2-thiophenecarboxamide is disclosed in WO-A 01/47919 and corresponds to the formula m CI
O N N` ' H

O
The compound of the formula (1) acts as inhibitor of clotting factor Xa and can be employed as agent for the prophylaxis and/or treatment of thromboembolic disorders, in particular myocardial infarction, angina pectoris (including unstable, angina), reocclusions and restenoses after angioplasty or aortocoronary bypass, stroke, transient ischaemic attacks, peripheral arterial occlusive diseases, pulmonary embolisms or deep venous thromboses.

WO-A 01/47919 also describes a method for preparing the compound of the formula (I) in the gram range starting from the same starting compounds 2-[(2,)-2-oxiranylmethyl]-1H-isoindole-1,3(2H)-dione (11), 4-(4-aminophenyl)-3-morpholinone (III) and 5-chlorothiophene-2-carbonyl chloride (IV):

O
NH
O \ / + _O _NH

N

N / \ N OH
,~,~N
\-i 0 (V) 0 BHC 03 1 094-Foreign Countries O
O N N\ 1O
/~N
O (VI) 0 S CI

O N - - & N \_i \_~NH2 O
(VID
CI
O
`-~ ~_p S
\\ N\__~N
O
(I) In this case, 2-[(2S)-2-oxiranylmethyl]-1H-isoindole-1,3(2H)dione (11) is reacted with 4-(4-aminophenyl)-3-morpholinone (III) to give 2-((2R)-2-hydroxy-3-{[4-(3-oxo-4-morpholinyl)-phenyl]amino }propyl)-1H-isoindole-1,3(211)dione (V). Subsequently, (V) is converted with a phosgene equivalent into 2-({(55)-2-oxo-3-[4-(3-oxo-4-morpholinyl)phenyl]-1,3-oxazolidin-5-yl}-methyl)-1H-isoindole-1,3(2H)dione (VI). Elimination of the phthalimide protective group affords 4-{4-[(5S)-5-(aminomethyl)-2-oxo-1,3-oxazolidin-3-yl]phenyl}morpholine-3-one (VII) which is finally reacted with 5-chlorothiophene-2-carbonyl chloride (IV) to give 5-chloro-N-({(5S)-2-oxo-3-[4-(3-oxo-4-morpholinyl)phenyl]-1,3-oxazolidin-5-yl}methyl)-2-thiophenecarboxamide (1).
However, this process disclosed in WO-A 01/47919 exhibits various disadvantages in the reaction management which has particularly unfavourable effects for preparation of the compound of the formula (1) on the industrial scale.

DE 10300111.5 discloses an alternative process for synthesizing the compound of the formula (1) starting from 5-chlorothiophene-2-carbonyl chloride (IV), (2S)-3-aminopropane-1,2-diol hydro-chloride (VIII) and 4-(4-aminophenyl)-3-morpholinone (III):

BHC 03 1 094-Foreign Countries
-3-0 HO"-~NH3CI 0 S Cl + OH HO~~~N S CI
CI H
OH
(IX) O + O N / \ NH2 S
CI
Br---~N
O
OH
(X) (III) - H OH O
O
N \ / N` N S CI (I ) \-i --11 \ ~/
O (XI) In this case, 5-chlorothiophene-2-carbonyl chloride (IV) is reacted with (2S)-3-aminopropane-1,2-diol hydrochloride (VIII) to give 5-chlorothiophene-2-carboxylic acid ((S)-2,3-dihydroxypropyl)-amide (IX). Subsequently, (IX) is converted into 5-chlorothiophene-2-carboxylic acid ((S)-3-bromo-2-hydroxypropyl)amide (X), which is then reacted with 4-(4-aminophenyl)-3-morpholinone (III) to give 5-chlorothiophene-2-carboxylic acid {(R)-2-hydroxy-3-[4-(3-oxomorpholin-4-yl)phenylamino]-propyl}amide (XI). Finally, (XI) is reacted with phosgene or a phosgene equivalent to give 5-chloro- N-({(5S)-2-oxo-3-[4-(3-oxo-4-morpholinyl)phenyl]-1,3-oxazolidin-5-yl}methyl)-2-thiophenecarboxamide (I).

This alternative synthesis can be carried out on an industrial scale, although toxic solvents or reagents are used in part. This is disadvantageous per se, and in addition these toxic substances must be removed from the final product (I) until below the maximum limit permissible in each case in the product for regulatory reasons, which signifies additional expense.

The object of the present invention derives therefrom, of providing a simplified process for preparing the compound (1) on the industrial scale, avoiding toxic solvents or reagents, especially in the last steps of the process.

It has now been found, surprisingly, that it is possible by modifying certain reaction parameters in the synthesis disclosed in WO-A 01/47919 to prepare the compound of the formula (I) optionally in larger amounts in good yield and purity.

BHC 03 1 094-Foreign Countries
-4-The present invention thus relates to a process for preparing 5-chloro-N-({(5S)-2-oxo-3-[4-(3-oxo-4-morpholinyl)phenyl]-1,3-oxazolidin-5-yl}methyl)-2-thiophenecarboxamide of the formula (I) by reacting 4-{4-[(5S)-5-(aminomethyl)-2-oxo-1,3-oxazolidin-3-yl]phenyl}morpholin-3-one (VII) hydrochloride with 5-chlorothiophene-2-carbonyl chloride (IV), characterized in that the reaction is carried out in a solvent selected from the group of ether, alcohol, ketone and water or in a mixture thereof with use of an inorganic base.

Examples of suitable and preferred solvents which may be mentioned are: ethers such as tetrahydrofuran, dioxane, diisopropyl ether or methyl tert-butyl ether;
alcohols such as methanol, ethanol, isopropanol, n-propanol, n-butanol, isobutanol, sec-butanol or tert-butanol; ketones such as methyl ethyl ketone, methyl isobutyl ketone or acetone or water or mixtures of two or more of the solvents listed.

Particularly preferred solvents are ketones or mixtures of ketones with water, especially acetone or, preferably, mixtures of acetone with water.

Examples of suitable and preferred inorganic bases which may be mentioned are:
alkali metal (e.g.
sodium and potassium) and alkaline earth metal (e.g. calcium and magnesium) hydroxides, alkali metal and alkaline earth metal carbonates or alkali metal and alkaline earth metal bicarbonates.
Particularly preferred as inorganic base are sodium hydroxide, sodium carbonate or sodium bicarbonate, especially sodium carbonate.

The reaction of aminomethyloxazolidinone (VII) hydrochloride with chlorothiophenecarbonyl chloride (IV) is preferably carried out in an acetone/water mixture as solvent with use of sodium carbonate as base.

The acetone/water ratio can in this case be varied over a wide range, and is preferably from 0.5 to 1.5 (v/v), in particular 0.9 to 1.1 (v/v).

In this way it is possible firstly to avoid the carcinogenic pyridine which is used as solvent and base in the process described in WO-A 01/47919. It is additionally possible according to the invention to avoid the clinically complicated chromatographic purification of the product (I).

The process according to the invention is carried out by preferably initially charging an aqueous sodium carbonate solution, into which firstly acetone and then aminomethyloxazolidinone (VU) hydrochloride and subsequently chlorothiophenecarbonyl chloride (IV) are introduced. The addition of the reactants preferably takes place at a temperature between 0 and 20 C, in particular between 10 and 15 C. After the addition has taken place, the reaction mixture is then stirred at a BHC 03 1 094-Foreign Countries
-5-temperature between 40 and 55 C, preferably at about 50 C. After cooling to room temperature, the product can then be isolated in a simple manner by filtration.

In a preferred embodiment of the present invention, the crude product of the compound of the formula (1) which is obtained by the filtration described above is recrystallized for further purification from acetic acid in a subsequent step.

Aminomethyloxazolidinone (VII) is prepared, as already disclosed also in WO-A
01/47919, by eliminating the phthalimide protective group from oxazolidinonemethylphthalimide (VI) with methylamine in ethanol as solvent. However, after the reaction has taken place, unlike the description in WO-A 01/47919, aqueous hydrochloric acid is then added at elevated temperature to the reaction mixture until the pH is between 1 and 4, preferably between 2 and 3. The addition takes place at elevated temperature, preferably at a temperature between 50 and 60 C. In this way, aminomethyloxazolidinone (VII) is isolated pure in the form of its hydrochloride, which in this case results as crystals and easily filterable, in a simple manner.

The process disclosed in WO-A 01/47919, in which the aminomethyloxazolidinone (VII) crude product obtained after concentration of the reaction mixture is directly employed in the further reaction with chlorothiophenecarbonyl chloride (IV), has by contrast the disadvantage that the secondary components of this reaction, which are present in the aminomethyloxazolidinone (VII) crude product, impede the subsequent preparation of the final product (1) and additionally contaminate the product (1). In contrast thereto, the use of aminomethyloxazolidinone (VII) isolated according to the invention as solid hydrochloride in pure form makes improved reaction management possible in the following reaction with chlorothiophenecarbonyl chloride (IV), with unwanted side reactions being avoided and a purer product being obtained, so that the elaborate chromatographic purification can be avoided.

Oxazolidinonemethylphthalimide (VI) is prepared, as already disclosed also in WO-A 01/47919, by cyclization of the hydroxyamino compound (V) with a phosgene equivalent, for example and preferably with N,N-carbonyldiimidazole. However, the reaction conditions differ from those disclosed in WO-A 01/47919 in that the reaction is carried out not in the presence of dimethylaminopyridine as catalyst and tetrahydrofuran as solvent but according to the invention without catalyst in N-methylpyrrolidone or toluene, preferably in toluene as solvent. This also makes it possible to isolate the resulting oxazolidinonemethylphthalimide (VI) by simple filtration, instead of by elaborate chromatographic purification.

The hydroxyamine (V) is prepared, as already disclosed also in WO-A 01/47919, by reacting (S)-epoxyphthalimide (II) with anilinomorpholinone (III) in aqueous ethanol as solvent at a reaction
-6-temperature of 60 C. However, unlike the disclosure in WO-A 01/47919, the ethanol/water ratio (v/v) is according to the invention 1:1 to 3:1, preferably 2:1 (v/v), instead of 9:1, and subsequent metering in of the precursor (II) is no longer necessary. Instead, the reaction mixture is stirred at a temperature between 55 and 65 C for between 24 and 48 hours, preferably about 36 hours.

In a preferred embodiment of the present invention, seed crystals of the reaction product (V) are added to the reaction mixture after the reaction has lasted one to two hours, so that the reaction product starts to crystallize out.

In a particularly preferred embodiment of the present invention, the reaction mixture is heated under reflux towards the end of the reaction time, with the suspension being retained, and is then cooled again to the reaction temperature between 55 and 65 C.

This heating to reflux is repeated where appropriate, the heating preferably taking place twice in total.

Synthesis of the (S)-epoxyphthalimide (H) starting compound is described for example in A.
Gutcait et al. Tetrahedron Asym_ 1996, 7, 1641. In addition, the substance is commercially available, for example from Daiso Ltd., Japan.

Synthesis of the anilinomorpholinone (III) starting compound is described in detail for example in WO-A 01/47919, page 55 to 57 or in DE 10342570.5.

The individual stages of the process according to the invention can be carried out under atmospheric, elevated or reduced pressure (e.g. from 0.5 to 5 bar). Unless indicated, otherwise, atmospheric pressure is generally used.

The invention is explained in detail below by a preferred exemplary embodiment, but is not restricted thereto. Unless indicated otherwise, all quantitative data related to percentages by weight.

BHC 03 1 094-Foreign Countries
-7-Synthesis of 5-chloro-N-({(5S)-2-oxo-3-[4-(3-oxo-4-morpholinyl)phenyl]-1,3-oxazolidin-5-yl}-methyl)-2-thiophenecarboxamide (1) a) 2-((2R)-2-Hydroxy-3-{[4-(3-oxo-4-morpholinyl)phenyl]amino) propyl)-1H-isoindole-1,3(2H)-dione (V) 1173 g of 2-[(2S)-2-oxiranylmethyl]-1H-isoindole-1,3(2H)dione (II) and 4-(4-aminophenyl)-3-morpholinone (lII) are mixed at 20 C with 6.7 1 of water and 14.4 1 of ethanol. The suspension is heated to 58 to 60 C, and the resulting solution is stirred for 36 hours.
After 2 hours, 5 g of crystalline 2-((2R)-2-hydroxy-3 - { [4-(3-oxo-4-morpholinyl)phenyl]amino) propyl)-1H-isoindole-1,3(2R)-dione (V) are added to the reaction mixture, after which the product starts to crystallize.
After cooling to 26 C, the precipitated reaction product is filtered off with suction, washed with ethanol and then dried.

Yield: 1522 g; equivalent to 81.4 % of theory.
Melting point: 215 C

b) 2-({(5S)-2-Oxo-3-[4-(3-oxo-4-morpholinyl)phenyl]-1,3-oxazolidin-5-yl}methyl)-IH-isoindole-1,3(2H)-dione (VI) 2641 g of 2-((2R)-2-hydroxy-3-{[4-(3-oxo-4-morpholinyl)phenyl]amino}propyl)-1H-isoindole-1,3(2H)-dione (V) are suspended in 22 1 of toluene and, at 19 C, 1300 g of N,N-carbonyl-diimidazole are added. The reaction mixture is subsequently heated under reflux for one hour and then, at 60 C, 4.5 1 of ethanol are added. After cooling to 25 to 30 C, the precipitated reaction product is filtered off with suction, washed with ethanol and then dried.

Yield: 2756 g; equivalent to 97.9 % of theory.
Melting point: 220.5 C

c) 4-{4-[(5S)-5-(Aminomethyl)-2-oxo-1,3-oxazolidin-3-yl]phenyl}morpholin-3-one (VII) 1360 g of 2-({(55)-2-oxo-3-[4-(3-oxo-4-morpholinyl)phenyl]-1,3-oxazolidin-5-yl}methyl)-1H-iso-indole-1,3(2H -dione (VI) are suspended in 10.2 1 of ethanol at 22 C, and 1103 g of methylamine solution (40% strength in water) are added. The reaction mixture is then heated to 60 to 63 C, and the resulting solution is stirred at this temperature for 2 hours. After cooling to 55 to 60 C, a total of 2348 g of hydrochloric acid solution (20% strength in water) is added until the pH is 2.7, after which the product starts to crystallize. After cooling to 20 C, the precipitated reaction product is filtered off with suction, washed with methanol and then dried.

Yield: 875 g; equivalent to 82.7 % of theory.

BHC 03 1 094-Foreign Countries
-8-Melting point: decomposition above 280 C

'H NMR (300 MHz, d6-DMSO): 3.25 (m, 2H), 3.72 (m, 2H), 3.98 (m, 3H), 4.42 (m, 3H), 4.97 (m, I H), 7.42 (d, 2H, J= 9.0 Hz), 7.57 (d, 2H, J= 9.0 Hz), 8.44 (s (br.), 3H) ppm.

d) 5-Chloro-N ({(5S)-2-oxo-3-[4-(3-oxo-4-morpholinyl)phenyl]-1,3-oxazolidin-5-yl}-methyl}
2-thiophenecarboxamide (1) 1st step: 5-chlorothiophene-2-carbonyl chloride (IV) 3.00 kg of 5-chlorothiophene-2-carboxylic acid (commercially available) are suspended in 8.48 kg of toluene and heated to 75 to 80 C. At this temperature, 2.63 kg of thionyl chloride are added dropwise over a period of 85 minutes, followed by stirring at 75 to 80 C for 30 minutes and then at the reflux temperature until gas evolution ceases. After cooling, the reaction mixture is distilled under reduced pressure with gradually increasing internal temperature (up to a maximum of 60 C) to remove excess thionyl chloride and toluene until an approximately 30%
strength solution of the acid chloride in toluene is produced.

2nd step: 5-Chloro-N-({(5S)-2-oxo-3-[4-(3-oxo-4-morpholinyl)phenyl)-1,3-oxazolidin-5-yl}-methyl)-2-thiophenecarboxamide (1) - crude product 1160 g of 4-{4-[(5S)-5-(aminomethyl)-2-oxo-1,3-oxazolidin-3-yl]phenyl}morpholin-3 -one (VII) hydrochloride, 350 ml of water and 2.7 1 of acetone are successively added to a solution of 464 g of sodium carbonate in 5.95 1 of water at 10 C. At 8 to 12 C, 2535 g of 5-chlorothiophene-2-carbonyl chloride (IV) (30% strength solution in toluene) and a further 517 ml of toluene are added. The reaction mixture is then heated to 50 C, 2700 ml of acetone are added, and the mixture is stirred at 50 to 53 C for a further 30 minutes. After cooling to 26 C, the precipitated reaction product is filtered off with suction and washed with water and acetone.

Yield: 1998 g of solvent-containing crude product.

The residual moisture content is found to be 24.3%, which corresponds to a calculated dry weight of 1505 g or 98.7 % of theory.

BHC 03 1 094-Foreign Countries
-9-3rd step: 5-Chloro-N-({(5S)-2-oxo-3-[4-(3-oxo-4-morpholinyl)phenyl)-1,3-oxazolidin-5-yl}-methyl)-2-thiophenecarboxamide (I) - recrystallization 2120 g of solvent-containing crude product (residual moisture content 9.4%) is suspended in 12 kg of acetic acid and heated to 110 to 115 C. The resulting solution is stirred at this temperature for
10 minutes and then, after clarifying filtration, cooled to 20 C. The precipitated product is filtered off with suction, washed with acetic acid and water and then dried.

Yield: 1818 g; equivalent to 94.7% of theory (based on the dry weight of the crude product).
Melting point: 230 C

Claims (12)

CLAIMS:
1. A process for preparing 5-chloro-N-({(5S)-2-oxo-3-[4-(3-oxo-4-morpholinyl)phenyl]-1,3-oxazolidin-5-yl}methyl)-2-thiophenecarboxamide of the formula (I) by reacting 4-{4-[(5S)-5-(aminomethyl)-2-oxo-1,3-oxazolidin-3-yl]phenyl}-morpholin-3-one (VII) hydrochloride with 5-chlorothiophene-2-carbonyl chloride (IV), wherein the reaction is carried out in a solvent, wherein the solvent is ether, alcohol, ketone or water or a mixture thereof, and with use of an inorganic base.
2. The process according to claim 1, wherein the reaction is carried out in a ketone or a mixture of ketone and water as the solvent.
3. The process according to claim 1 or 2, wherein the reaction is carried out with sodium hydroxide, sodium carbonate or sodium bicarbonate as the inorganic base.
4. The process according to any one of claims 1 to 3, wherein the reaction is carried out in an acetone/water mixture as the solvent with use of sodium carbonate as the inorganic base.
5. The process according to any one of claims 1 to 4, wherein an aqueous sodium carbonate solution is initially charged, and the reactants are added at a temperature between and 15°C, and the reaction mixture is then stirred at 50°C.
6. The process as defined in any one of claims 1 to 5, wherein the compound of the formula (I) is obtained as a crude product and the crude product is then recrystallized from acetic acid in a subsequent step.
7. The process as defined in any one of claims 1 to 6, where 4-{4-[(5S)-5-(aminomethyl)-2-oxo-1,3-oxazolidin-3-yl]phenyl}morpholin-3-one (VII) hydrochloride is prepared by eliminating the phthalimide protective group from 2-({(5S)-2-oxo-3-[4-(3-oxo-4-morpholinyl)phenyl]-l,3-oxazolidin-5-yl}methyl)-1H-isoindole-1,3(2H)-dione (VI) with methylamine in ethanol as solvent, wherein reaction of 2-({(5S)-2-oxo-3-[4-(3-oxo-4-morpholinyl)phenyl]-1,3-oxazolidin-5-yl}methyl)-1H-isoindole-l,3(2H)-dione (VI) with methylamine is followed by addition of aqueous hydrochloric acid to the reaction mixture at a temperature between 50 and 60°C until the pH is between 2 and 3 and wherein the 4-{4-[(5S)-5-(aminomethyl)-2-oxo-1,3-oxazolidin-3-yl]phenyl}morpholin-3-one (VII) is isolated as solid hydrochloride.
8. The process as defined in claim 7, where 2-({(5S)-2-oxo-3-[4-(3-oxo-4-morpholinyl)phenyl]-1,3-oxazolidin-5-yl}methyl)-1H-isoindole-l,3(2H)-dione (VI) is prepared by cyclization of 2-((2R)-2-hydroxy-3-{[4-(3-oxo-4-morpholinyl)phenyl]amino}propyl)-1H-isoindole-1,3(2H)-dione (V) with a phosgene equivalent, and wherein the cyclization reaction is carried out in toluene as the solvent.
9. The process as defined in claim 8, wherein 2-({(5S)-2-oxo-3-[4-(3-oxo-4-morpholinyl)phenyl]-1,3-oxazolidin-5-yl}methyl)-1H-isoindole-1,3(2H)-dione (VI) is isolated by filtration.
10. The process as defined in claim 8 or 9, where 2-((2R)-2-hydroxy-3-{[4-(3-oxo-4-morpholinyl)phenyl]amino}-propyl)-1H-isoindole-1,3(2H)-dione (V) is prepared by reacting 2-[(2S)-2-oxiranylmethyl]-1H-isoindole-1,3(2H)dione (II) with 4-(4-aminophenyl)-3-morpholinone (III) in aqueous ethanol as solvent, and wherein the ethanol/water ratio is 2:1.
11. The process as defined in claim 10, wherein seed crystals of 2-((2R)-2-hydroxy-3-{[4-(3-oxo-4-morpholinyl)-phenyl]amino}propyl)-1H-isoindole-1,3(2H)-dione (V) are added to the reaction mixture after the reaction has lasted from one to two hours.
12. The process as defined in claim 11, wherein the reaction mixture is heated under reflux twice towards the end of the reaction time and on each occasion is subsequently cooled again to the reaction temperature of between 55 and 65°C.
CA2553237A 2004-01-15 2004-12-31 Production method Active CA2553237C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE102004002044.2 2004-01-15
DE102004002044A DE102004002044A1 (en) 2004-01-15 2004-01-15 manufacturing
PCT/EP2004/014870 WO2005068456A1 (en) 2004-01-15 2004-12-31 Production method

Publications (2)

Publication Number Publication Date
CA2553237A1 CA2553237A1 (en) 2005-07-28
CA2553237C true CA2553237C (en) 2012-04-17

Family

ID=34716548

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2553237A Active CA2553237C (en) 2004-01-15 2004-12-31 Production method

Country Status (33)

Country Link
US (1) US7351823B2 (en)
EP (1) EP1720866B1 (en)
JP (2) JP5311742B2 (en)
KR (1) KR20130004257A (en)
CN (1) CN1906191B (en)
AR (1) AR047389A1 (en)
AT (1) ATE518856T1 (en)
AU (1) AU2004313694B2 (en)
BR (1) BRPI0418405B8 (en)
CA (1) CA2553237C (en)
CY (1) CY1112565T1 (en)
DE (1) DE102004002044A1 (en)
DK (1) DK1720866T3 (en)
EC (1) ECSP066703A (en)
ES (1) ES2369140T3 (en)
GT (1) GT200400277A (en)
HK (1) HK1103722A1 (en)
HN (1) HN2005000016A (en)
HR (1) HRP20110796T1 (en)
IL (1) IL176767A (en)
MA (1) MA28290A1 (en)
MY (1) MY138944A (en)
NO (1) NO335553B1 (en)
NZ (1) NZ548506A (en)
PE (1) PE20050763A1 (en)
PL (1) PL1720866T3 (en)
PT (1) PT1720866E (en)
RU (1) RU2383540C2 (en)
SI (1) SI1720866T1 (en)
TW (1) TWI340137B (en)
UY (1) UY28718A1 (en)
WO (1) WO2005068456A1 (en)
ZA (1) ZA200605747B (en)

Families Citing this family (81)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19962924A1 (en) 1999-12-24 2001-07-05 Bayer Ag Substituted oxazolidinones and their use
DE10129725A1 (en) * 2001-06-20 2003-01-02 Bayer Ag Combination therapy of substituted oxazolidinones
DE10300111A1 (en) * 2003-01-07 2004-07-15 Bayer Healthcare Ag Process for the preparation of 5-chloro-N - ({(5S) -2-oxo-3- [4- (3-oxo-4-morpholinyl) phenyl] -1,3-oxazolidin-5-yl} methyl ) -2-thiophenecarboxamide
DE10355461A1 (en) 2003-11-27 2005-06-23 Bayer Healthcare Ag Solid, high bioavailabilty oral formulations of N-substituted 5-chloro-2-thiophene-carboxamide derivative in hydrophilized form, useful for combating thrombo-embolic diseases
DE102004062475A1 (en) * 2004-12-24 2006-07-06 Bayer Healthcare Ag Solid, orally administrable, modified release pharmaceutical dosage forms
EP1685841A1 (en) 2005-01-31 2006-08-02 Bayer Health Care Aktiengesellschaft Prevention and treatment of thromboembolic disorders
DE102005045518A1 (en) * 2005-09-23 2007-03-29 Bayer Healthcare Ag New 5-thienylaminocarbonylmethyl-oxazolidin-2-one derivatives, useful for treating and preventing thromboembolic disease, are selective inhibitors of coagulation factor Xa
SG166126A1 (en) * 2005-10-04 2010-11-29 Bayer Schering Pharma Ag Novel polymorphous form and the amorphous form of 5-chloro-n-({(5s)-2-oxo- 3-[4-(3-oxo-4-morpholinyl)-phenyl]-1,3-oxazolidine-5-yl}-methyl)-2-thiophene carboxamide
DE102005047561A1 (en) 2005-10-04 2007-04-05 Bayer Healthcare Ag Drug delivery system, useful to treat and/or prevent e.g. thromboembolic disease, comprises 5-chloro-N-(((5S)-2-oxo-3-(4-(3-oxo-4-morpholinyl)-phenyl)-1,3-oxazolidine-5-yl)-methyl)-2-thiophene carboxamide with fast release active substance
DE102005047558A1 (en) * 2005-10-04 2008-02-07 Bayer Healthcare Ag Combination therapy of substituted oxazolidinones for the prophylaxis and treatment of cerebral circulatory disorders
DE102005047564A1 (en) * 2005-10-04 2007-05-31 Bayer Healthcare Ag New forms of specific substituted thiophene carboxamide (rivaroxaban), useful for prevention and treatment of thromboembolic disease, have higher solubility than known modifications
DE102006007146A1 (en) 2006-02-16 2007-08-23 Bayer Healthcare Ag Aminoacyl prodrugs
DE102006039589A1 (en) * 2006-08-24 2008-03-06 Bayer Healthcare Ag Aminoacyl prodrugs II
DE102006051625A1 (en) * 2006-11-02 2008-05-08 Bayer Materialscience Ag Combination therapy of substituted oxazolidinones
DE102007028407A1 (en) * 2007-06-20 2008-12-24 Bayer Healthcare Ag Substituted oxazolidinones and their use
DE102007028319A1 (en) * 2007-06-20 2008-12-24 Bayer Healthcare Ag Substituted oxazolidinones and their use
WO2009018807A1 (en) * 2007-08-06 2009-02-12 Schebo Biotech Ag Novel pharmaceuticals, method for the production thereof, and use thereof in therapy
US8706950B2 (en) 2008-03-01 2014-04-22 Kabushiki Kaisha Toshiba Memory system
DE102008028071A1 (en) 2008-06-12 2009-12-17 Bayer Schering Pharma Aktiengesellschaft New cocrystal compound of rivaroxaban and malonic acid
US20100168111A1 (en) * 2008-12-31 2010-07-01 Apotex Pharmachem Inc. Polymorphic form of 5 chloro n {[(5s) 2 oxo 3 [4 (3 oxomorpholin 4 yl)phenyl]oxa-zolidin 5 yl]-methyl}thiophene 2 carboxamide
US8435989B2 (en) * 2009-04-28 2013-05-07 Apotex Pharmachem Inc. Processes for the preparation of rivaroxaban and intermediates thereof
US7816355B1 (en) * 2009-04-28 2010-10-19 Apotex Pharmachem Inc Processes for the preparation of rivaroxaban and intermediates thereof
US8309547B2 (en) * 2009-04-28 2012-11-13 Apotex Pharmachem Inc. Processes for the preparation of rivaroxaban and intermediates thereof
PL2459555T3 (en) 2009-07-31 2022-03-28 Krka, D.D., Novo Mesto Processes for crystallization of rivaroxaban
EP2521723A1 (en) * 2010-01-04 2012-11-14 Enantia, S.L. Process for the preparation of rivaroxaban and intermediates thereof
DE102010028362A1 (en) 2010-04-29 2011-11-03 Bayer Schering Pharma Aktiengesellschaft manufacturing
EP2388260A1 (en) * 2010-05-21 2011-11-23 Archimica GmbH Method for producing a blood coagulation factor inhibitor
CN102311400A (en) * 2010-06-29 2012-01-11 翔真生物科技股份有限公司 Method for preparing 5(S)-aminomethyl-3-aryl-2-oxazolidinone
EP2404920A1 (en) 2010-07-06 2012-01-11 Sandoz AG Crystalline form of Rivaroxaban dihydrate
US20130253187A1 (en) 2010-09-14 2013-09-26 Medichem, S.A. Process for Determining the Suitability for Distribution of a Batch of Thiophene-2-Carboxamide Derivative
CZ2010714A3 (en) * 2010-09-30 2012-04-11 Farmak, A. S. Process for preparing extreme optically pure 2-({(5S)-2-oxo-3-[4-(3-oxo-4-morpholinyl)phenyl]-1,3oxazolidin-5-yl}methyl)-1H-isoindole-1,3(2H)-dione
CA2815063C (en) 2010-10-18 2016-11-22 Apotex Pharmachem Inc. Processes for the preparation of rivaroxaban and intermediates thereof
MD4557C1 (en) * 2011-05-06 2018-10-31 Egis Gyogysszegyar Nyilvanosan Mukodo Reszvenytarsasag Process for the preparation of rivaroxaban and an intermediate used in said process
WO2012156983A1 (en) * 2011-05-16 2012-11-22 Symed Labs Limited Processes for the preparation of 5-chloro-n-({(5s)-2-oxo-3-[4-(3-oxo-4-morpholinyl) phenyl]-1,3-oxazolidin-5-yl}methyl)-2-thiophenecarboxamide
ES2395304B1 (en) 2011-05-20 2014-01-16 Interquim, S.A. PROCEDURE FOR OBTAINING A THIOPHEN-2-CARBOXAMIDE.
CN102250076A (en) * 2011-05-27 2011-11-23 横店集团家园化工有限公司 Preparation method for rivaroxaban intermediate and rivaroxaban
CN102827154B (en) 2011-06-14 2015-04-22 上海科胜药物研发有限公司 New method for synthesizing rivaroxaban intermediate 4-{4-[(5S)-5-(aminomethyl)-2-oxo-1,3-oxazolidine-3-yl]phenyl}morpholine-3-ketone
EP2753619A2 (en) 2011-09-08 2014-07-16 Cadila Healthcare Limited Processes and intermediates for preparing rivaroxaban
WO2013053739A1 (en) 2011-10-10 2013-04-18 Laboratorios Lesvi, S. L. Process for preparing factor xa inhibitors
EP2812329A2 (en) * 2012-02-06 2014-12-17 Megafine Pharma (P) Ltd. A process for preparation of rivaroxaban and intermediates thereof
CZ2012114A3 (en) * 2012-02-17 2013-02-20 Zentiva, K.S. Process for preparing rivaroxaban based on saving of 1,1?-carbonyldiimidazole
CN103288814B (en) 2012-02-24 2016-07-06 国药集团国瑞药业有限公司 A kind of preparation method of Rivaroxaban intermediate
CN102659756A (en) * 2012-04-01 2012-09-12 南京哈柏医药科技有限公司 Method for synthesis of 5-chlorothiophene-2-carbonyl chloride
US9562040B2 (en) 2012-04-06 2017-02-07 Indiana University Research And Technology Corporation Processes for preparing Rivaroxaban
CN104487436B (en) 2012-05-02 2017-05-24 信谊实验室有限公司 Improved process for preparing rivaroxaban using intermediates
CN102757424B (en) * 2012-07-09 2014-10-15 云南大学 2-benzyl-substituted-benzofuran-imidazolium compounds and preparation method thereof
CN102746288B (en) * 2012-07-24 2015-04-08 常州制药厂有限公司 Preparation methods of anticoagulant and key intermediate of anticoagulant
WO2014020458A1 (en) * 2012-08-01 2014-02-06 Alembic Pharmaceuticals Limited Improved process for preparation of rivaroxaban
CN102786516B (en) * 2012-08-21 2014-10-01 湖南师范大学 Method for synthesizing rivaroxaban
CN103833724A (en) * 2012-11-20 2014-06-04 上海医药工业研究院 Preparation method of 5-penphene-2-formyl chloride
CN103864771A (en) * 2012-12-13 2014-06-18 北京京卫信康医药科技发展有限公司 Rivaroxaban preparation method
CN103864772A (en) * 2012-12-13 2014-06-18 北京京卫信康医药科技发展有限公司 Preparation method for rivaroxaban and intermediate thereof
EP3309158B1 (en) 2012-12-21 2022-03-16 Krka, tovarna zdravil, d.d. Crystalline form k of rivaroxaban and process for its preparation
PT2895176T (en) 2012-12-26 2017-01-27 Wanbury Ltd Rivaroxaban intermediate and preparation thereof
AU2013368847B2 (en) 2012-12-26 2017-03-16 Wanbury Ltd. Aldehyde derivative of substitute oxazolidinones
WO2014155259A2 (en) 2013-03-25 2014-10-02 Glenmark Pharmaceuticals Limited; Glenmark Generics Limited Process for the preparation of rivaroxaban
CN104109158A (en) * 2013-04-16 2014-10-22 上海医药工业研究院 Rivaroxaban purification method
CN103275061A (en) * 2013-06-04 2013-09-04 上海同昌生物医药科技有限公司 Method for producing 5-chlorothiophene-2-carboxylic acid
CN103351385A (en) * 2013-06-28 2013-10-16 浙江燎原药业有限公司 Preparation method for rivaroxaban intermediate
CN103709116B (en) * 2013-12-10 2015-09-23 四川大学 A kind of preparation method of 4-(4-alkoxycarbonylamino) phenyl-3-morpholone mai
CN103724336B (en) * 2013-12-24 2015-10-21 悦康药业集团有限公司 A kind of synthetic method of novel anticoagulation medicine
WO2015104605A1 (en) 2014-01-08 2015-07-16 Wockhardt Limited A process for preparing rivaroxaban or a pharmaceutically acceptable salt thereof
IN2014CH00290A (en) 2014-01-23 2015-08-14 Symed Labs Ltd
CN105085370B (en) * 2014-04-22 2017-04-12 北大方正集团有限公司 (S)-1-halo-2-[2-(1,3-dioxo-isoindol)yl]ethyl chloroformate and preparation method thereof
CN105693746B (en) * 2014-06-14 2018-09-14 广东东阳光药业有限公司 The Preparation Method And Their Intermediate of oxazolidinone compounds
CN104086539A (en) * 2014-07-17 2014-10-08 天津炜捷制药有限公司 Preparation method of rivaroxaban
CN104211693B (en) * 2014-08-07 2017-02-22 成都百裕制药股份有限公司 Rivaroxaban crystalline form, preparation method and application
CN104211694A (en) * 2014-08-14 2014-12-17 广东东阳光药业有限公司 Improved method for preparing Xa factor inhibitor
WO2016030669A1 (en) * 2014-08-25 2016-03-03 Cipla Limited Process for the preparation of rivaroxaban
EA034656B1 (en) 2014-10-22 2020-03-03 Закляды Фармацеутычне Польфарма С.А Process for preparing a polymorph of rivaroxaban
CN104807934B (en) * 2015-04-30 2017-01-18 成都百裕制药股份有限公司 Normal-phase high performance liquid chromatography detection method of isoindole diketone compounds
CN105130976A (en) * 2015-08-26 2015-12-09 浙江车头制药股份有限公司 Method for synthesizing rivaroxaban intermediate
CN105440028B (en) * 2015-12-07 2018-03-13 石家庄康贺威药业有限公司 A kind of razaxaban compound and preparation method thereof
CN106008490B (en) * 2016-01-11 2019-01-04 南京生命能科技开发有限公司 A kind of new crystal of razaxaban and preparation method thereof
CN106977507A (en) * 2017-04-21 2017-07-25 上海华源医药科技发展有限公司 A kind of preparation method of razaxaban
CN109553611A (en) * 2017-09-23 2019-04-02 齐鲁制药有限公司 The preparation method and purposes of Rivaroxaban intermediate
IL275443B (en) * 2018-02-26 2022-07-01 Sumitomo Chemical Co Production method for oxazolidinone compound
JP7339754B2 (en) * 2019-03-27 2023-09-06 ダイト株式会社 Method for producing intermediates
CN112521380A (en) * 2020-12-14 2021-03-19 哈尔滨珍宝制药有限公司 Synthetic method of rivaroxaban intermediate A and application of rivaroxaban intermediate A in preparation of rivaroxaban
US20240262834A1 (en) * 2021-05-28 2024-08-08 Merck Sharp & Dohme Llc Synthesis of btk inhibitor and intermediates thereof
EP4201933A1 (en) 2021-12-23 2023-06-28 Zaklady Farmaceutyczne Polpharma S.A. Crystallisation process for rivaroxaban

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19962924A1 (en) * 1999-12-24 2001-07-05 Bayer Ag Substituted oxazolidinones and their use
DE10129725A1 (en) * 2001-06-20 2003-01-02 Bayer Ag Combination therapy of substituted oxazolidinones
DE10300111A1 (en) * 2003-01-07 2004-07-15 Bayer Healthcare Ag Process for the preparation of 5-chloro-N - ({(5S) -2-oxo-3- [4- (3-oxo-4-morpholinyl) phenyl] -1,3-oxazolidin-5-yl} methyl ) -2-thiophenecarboxamide

Also Published As

Publication number Publication date
US7351823B2 (en) 2008-04-01
TW200604195A (en) 2006-02-01
CA2553237A1 (en) 2005-07-28
HN2005000016A (en) 2009-06-01
TWI340137B (en) 2011-04-11
JP5311742B2 (en) 2013-10-09
BRPI0418405B1 (en) 2018-03-13
AU2004313694A1 (en) 2005-07-28
KR20130004257A (en) 2013-01-09
NO20063677L (en) 2006-10-11
ATE518856T1 (en) 2011-08-15
CN1906191A (en) 2007-01-31
JP2012097106A (en) 2012-05-24
BRPI0418405A (en) 2007-05-15
MY138944A (en) 2009-08-28
ES2369140T3 (en) 2011-11-25
UY28718A1 (en) 2005-08-31
CY1112565T1 (en) 2016-02-10
CN1906191B (en) 2010-05-26
RU2006129341A (en) 2008-02-20
AU2004313694B2 (en) 2011-06-02
NO335553B1 (en) 2014-12-29
WO2005068456A1 (en) 2005-07-28
HRP20110796T1 (en) 2011-12-31
GT200400277A (en) 2005-08-18
BRPI0418405B8 (en) 2021-05-25
US20050182055A1 (en) 2005-08-18
ZA200605747B (en) 2007-10-31
IL176767A (en) 2011-04-28
DK1720866T3 (en) 2011-11-21
IL176767A0 (en) 2006-10-31
EP1720866A1 (en) 2006-11-15
HK1103722A1 (en) 2007-12-28
PL1720866T3 (en) 2012-01-31
AR047389A1 (en) 2006-01-18
MA28290A1 (en) 2006-11-01
PE20050763A1 (en) 2005-12-02
NZ548506A (en) 2009-06-26
SI1720866T1 (en) 2012-01-31
RU2383540C2 (en) 2010-03-10
DE102004002044A1 (en) 2005-08-04
ECSP066703A (en) 2006-10-31
EP1720866B1 (en) 2011-08-03
PT1720866E (en) 2011-10-12
JP2007517816A (en) 2007-07-05

Similar Documents

Publication Publication Date Title
CA2553237C (en) Production method
CA2512504C (en) Method for producing 5-chloro-n-({5s)-2-oxo-3-[4-(3-oxo-4-morpholinyl)-phenyl]-1,3-oxazolidin-5-yl}methyl)-2-thiophenecarboxamide
JP5274725B2 (en) Preparation method of rivaroxaban
JP6325978B2 (en) Process for the preparation of rivaroxaban and intermediates formed in the process
KR20120104077A (en) Processes for the preparation of rivaroxaban and intermediates thereof
SK179699A3 (en) Novel 2-(iminomethyl)amino-phenyl derivatives, preparation, application as medicines and compositions containing same
AU2011300365A1 (en) Processes for the preparation of 4-{4-[5(S)-(aminomethyl)-2-oxo-1,3-oxazolidin-3-yl]phenyl} morpholin-3-one
AU2012378913A1 (en) Improved process for preparing rivaroxaban using novel intermediates
CN103360379A (en) Novel oxazolidinone compound
CN104592143B (en) The preparation method of Yi Zhong oxazolidinone compounds
WO2012041263A2 (en) A method of manufacturing 2-({(5s)-2-oxo-3-[4-(3-oxo-4-morpholinyl)phenyl]- l,3-oxazolidin-5-yl}methyl)-lh-isoindol-l,3(2h)-dione with a high optical purity
KR101206598B1 (en) Production method
WO2016030669A1 (en) Process for the preparation of rivaroxaban
WO2014020458A1 (en) Improved process for preparation of rivaroxaban
MXPA06007902A (en) Production method
CN104860904B (en) N-glycidyl-N-anilid compounds Preparation Method And The Use
CN104370854A (en) 3-halogen-2-hydroxypropyl-1-acyl aniline compound, preparation method and applications thereof

Legal Events

Date Code Title Description
EEER Examination request